Viyash Scientific Ltd vs Wanbury Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Viyash Scientific Ltd is ₹ 206.2 as of 04 May 11:02 . The P/E Ratio of Viyash Scientific Ltd changed from 62.7 on March 2021 to 150.3 on March 2025 . This represents a CAGR of 19.11% over 5 yearsThe P/E Ratio of Wanbury Ltd changed from 3.4 on March 2022 to 25.2 on March 2025 . This represents a CAGR of 65.00% over 4 years The Market Cap of Viyash Scientific Ltd changed from ₹ 5983 crore on March 2021 to ₹ 3273 crore on March 2025 . This represents a CAGR of -11.36% over 5 yearsThe Market Cap of Wanbury Ltd changed from ₹ 207.5 crore on March 2021 to ₹ 768.96 crore on March 2025 . This represents a CAGR of 29.95% over 5 years The revenue of Viyash Scientific Ltd for the Dec '25 is ₹ 872.39 crore as compare to the Sep '25 revenue of ₹ 857.76 crore. This represent the growth of 1.71% The revenue of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Viyash Scientific Ltd for the Dec '25 is ₹ 148.35 crore as compare to the Sep '25 ebitda of ₹ 178.99 crore. This represent the decline of -17.12% The ebitda of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Viyash Scientific Ltd changed from ₹ 9.06 crore to ₹ 48.52 crore over 7 quarters. This represents a CAGR of 160.89% The net profit of Wanbury Ltd changed from ₹ 1.04 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Viyash Scientific Ltd changed from 38.67 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Wanbury Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Viyash Scientific Ltd

Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself.
The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on Nov 12, 2003.

About Wanbury Ltd

Wanbury Limited, formerly known Pearl Organics Limited was incorporated in August, 1988.
The Company attained its present name in September 2004.
The Company is engaged in the business of pharmaceutical and related activities, including research. The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.
In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga.
In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US. In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007.

FAQs for the comparison of Viyash Scientific Ltd and Wanbury Ltd

Which company has a larger market capitalization, Viyash Scientific Ltd or Wanbury Ltd?

Market cap of Viyash Scientific Ltd is 8,918 Cr while Market cap of Wanbury Ltd is 901 Cr

What are the key factors driving the stock performance of Viyash Scientific Ltd and Wanbury Ltd?

The stock performance of Viyash Scientific Ltd and Wanbury Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Viyash Scientific Ltd and Wanbury Ltd?

As of May 4, 2026, the Viyash Scientific Ltd stock price is INR ₹204.15. On the other hand, Wanbury Ltd stock price is INR ₹257.9.

How do dividend payouts of Viyash Scientific Ltd and Wanbury Ltd compare?

To compare the dividend payouts of Viyash Scientific Ltd and Wanbury Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.